Research News and Research

RSS

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

A $1 million grant from Abraxis Bioscience, Inc. to a world-famous research laboratory at John Wayne Cancer Institute at Saint John’s Health Center could help save lives of cancer patients by helping doctors more rapidly assess whether a treatment is working or not.

12 Jan 2010

Skeptics question health overhaul savings, cost-controls

USA Today reports that independent analysts are increasingly questioning whether the long-term savings promised in the health care bills being considered by Congress are realistic.

12 Jan 2010

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

12 Jan 2010

3D structure of PI3Kdelta: An important drug target for a wide range of diseases

Intellikine announced today the publication of an article entitled, "The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors," now available as an advanced online publication at Nature Chemical Biology.

12 Jan 2010

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.

12 Jan 2010

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

miRagen Therapeutics establishes SAB

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

Madison Williams launches Healthcare Investment Banking and Research business

Madison Williams and Company, an integrated capital markets and advisory firm, announced today the formal launch of a focused Healthcare Investment Banking and Research business. Madison Williams recently completed a management buyout of the principal capital markets business from Sanders Morris Harris Group in December 2009. The new firm already has a leading franchise in the Energy sector, and is quickly establishing its presence in healthcare with key new hires.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Public health and environment at risk: Large tobacco company influences EU policymaking

One of the world's largest tobacco companies has been instrumental in pushing through fundamental changes to EU policymaking, researchers from the University of Bath have found.

12 Jan 2010

Product quality becomes important to end users in sterilisation and disinfection equipment market

Due to the lack of adequate financing and weak healthcare infrastructure, price sensitivity within the Eastern European sterilisation and disinfection equipment market remains high.

12 Jan 2010

Market for chronic tophaceous gout medications will be led by drug that resolves tophi in less than a year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the U.S. and Europe, a drug that resolves tophi in less than one year would become the patient share leader in the chronic tophaceous gout patient subpopulation and would be used in the vast majority of patients who suffer severe tophaceous gout, according to surveyed U.S. and European rheumatologists.

12 Jan 2010

Experts to present latest research findings on reproductive medicine at ESHRE 26th annual meeting

Reproductive medicine is one of the most exciting scientific and clinical areas. Every month different announcements of research developments, medical 'firsts', new rulings by regulatory bodies, or ethical controversies are published and often spark a heated debate among practitioners in the field, as well as ethicists, legislators, the media and the public.

12 Jan 2010

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease.

12 Jan 2010

Stanford University School of Medicine adopts new, industry-funded model for continuing physicians’ education

Stanford University School of Medicine has developed a new, industry-funded model for the continuing education of physicians that aims to improve patient care while ensuring that corporate donors do not exert influence over the curriculum.

12 Jan 2010

SAC named alpha site for AQI's first national anesthesia data registry

Southeast Anesthesiology Consultants (SAC) has become an alpha site for the first national anesthesia data registry developed by the Anesthesia Quality Institute (AQI).

12 Jan 2010

Synexus finalises acquisition of ClinPharm at the start of 2010

Following their recent announcement of the deal to acquire German company, ClinPharm, Manchester-based Synexus is celebrating the start of 2010 with the news that the acquisition has now been finalised. This increases the number of Synexus dedicated research centres to twenty-six.

From AES - Accelerated Enrollment Solutions 12 Jan 2010

Curemark retains Rubenstein Public Relations

Curemark, a drug research and development company that focuses on the treatment of neurological diseases, has retained Rubenstein Public Relations to help raise national, regional, and industry awareness of the organization's research, treatments and founder, Dr. Joan Fallon. Curemark is developing an autism treatment that will be one of the first to address the underlying physiology of autism.

12 Jan 2010

Research News and Research

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

Skeptics question health overhaul savings, cost-controls

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

3D structure of PI3Kdelta: An important drug target for a wide range of diseases

Older patients with acute myeloid leukemia may benefit from decitabine drug

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

miRagen Therapeutics establishes SAB

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Madison Williams launches Healthcare Investment Banking and Research business

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Public health and environment at risk: Large tobacco company influences EU policymaking

Product quality becomes important to end users in sterilisation and disinfection equipment market

Market for chronic tophaceous gout medications will be led by drug that resolves tophi in less than a year

Experts to present latest research findings on reproductive medicine at ESHRE 26th annual meeting

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Stanford University School of Medicine adopts new, industry-funded model for continuing physicians’ education

SAC named alpha site for AQI's first national anesthesia data registry

Synexus finalises acquisition of ClinPharm at the start of 2010

Curemark retains Rubenstein Public Relations

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News